Glycogen storage disease type IX
Last updated 18 Aug 2020
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Glycogen storage disease type IX (also known as GSD IX) is a condition caused by the inability to break down a complex sugar called glycogen. The different forms of the condition can affect glycogen breakdown in liver cells or muscle cells or sometimes both. A lack of glycogen breakdown interferes with the normal function of the affected tissue.
Video picks for Genetic conditionsVideo library
Description
Glycogen storage disease type IX (also known as GSD IX) is a condition caused by the inability to break down a complex sugar called glycogen. The different forms of the condition can affect glycogen breakdown in liver cells or muscle cells or sometimes both. A lack of glycogen breakdown interferes with the normal function of the affected tissue.
When GSD IX affects the liver, the signs and symptoms typically begin in early childhood. The initial features are usually an enlarged liver (hepatomegaly) and slow growth. Affected children are often shorter than normal. During prolonged periods without food (fasting), affected individuals may have low blood sugar (hypoglycemia) or elevated levels of ketones in the blood (ketosis). Ketones are molecules produced during the breakdown of fats, which occurs when stored sugars are unavailable. Affected children may have delayed development of motor skills, such as sitting, standing, or walking, and some have mild muscle weakness. Puberty is delayed in some adolescents with GSD IX. In the form of the condition that affects the liver, the signs and symptoms usually improve with age. Typically, individuals catch up developmentally, and adults reach normal height. However, some affected individuals have a buildup of scar tissue (fibrosis) in the liver, which can rarely progress to irreversible liver disease (cirrhosis).
GSD IX can affect muscle tissue, although this form of the condition is very rare and not well understood. The features of this form of the condition can appear anytime from childhood to adulthood. Affected individuals may experience fatigue, muscle pain, and cramps, especially during exercise (exercise intolerance). Most affected individuals have muscle weakness that worsens over time. GSD IX can cause myoglobinuria, which occurs when muscle tissue breaks down abnormally and releases a protein called myoglobin that is excreted in the urine. Myoglobinuria can cause the urine to be red or brown.
In a small number of people with GSD IX, the liver and muscles are both affected. These individuals develop a combination of the features described above, although the muscle problems are usually mild.
Inheritance patterns
The source lists the following possible inheritance patterns: X-linked recessive; Autosomal recessive. More than one pattern can apply in different cases.
Related genes
Other names
GSD IX
GSDIX
PhK deficiency
Phosphorylase b kinase deficiency
Phosphorylase kinase deficiency
Patient picks for Genetic conditions

Children's health
Glycogen storage disorders
Glycogen storage disorders are a group of inherited diseases. They result from a problem with one of the proteins (known as enzymes) involved in the conversion of glucose to glycogen, or the breakdown of glycogen back into glucose. They mostly tend to affect your liver and muscles. Most are diagnosed in childhood. Symptoms include weakness, tiredness and low blood sugar levels. Newer treatment possibilities provide hope for an improved outlook (prognosis). Most people with a glycogen storage disorder respond well to treatment. However, type II (infantile Pompe's disease) can be difficult to treat and can affect life expectancy.
by Dr Roger Henderson, MBBS

Kidney and urinary tract
IgA nephropathy
IgA nephropathy is a condition in which a protein causes damage to the kidneys. The protein is called immunoglobulin A or IgA. Nephropathy means an illness that damages the kidney.
by Dr Colin Tidy, MRCGP

Diabetes
MHRA approves teplizumab to delay progression of type 1 diabetes
Teplizumab (Tzield) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to help delay the onset of Stage 3 type 1 diabetes (T1D). Read on to see what this means if you are prescribed teplizumab and what it does for you.
by Lawrence Higgins

Diabetes
Changes in type 2 diabetes care - what it means for you
If you are living with type 2 diabetes your treatment may soon change to be tailored around you and your specific needs - which will help improve your long-term health. Read on to find out what the changes are and what they mean for you.
by Lawrence Higgins

Diabetes
Video: How do you know if you have type 2 diabetes?
There are a lot of symptoms involved with type 2 diabetes, some of which may be mistaken for something else. Our experts look at what you need to look out for, and answer some other common questions about this widespread condition.
by Dr Partha Kar, FRCP

Heart health and blood vessels
Heart disease
The heart is a muscle pump located in the chest, which pumps blood around the body. It keeps pumping from a few weeks after conception until we die. There are a number of different conditions that can affect how the heart works.
by Dr Rachel Hudson, MRCGP
Related patient information and medicines

Patient information leaflet
Glycogen storage disorders
Glycogen storage disorders are a group of inherited diseases. They result from a problem with o... Glycogen storage disorders are a group of inherited diseases that result from a lack of, or abnormal functioning of, one of the proteins (enzymes) involved in the conversion of glucose to glycogen or the breakdown of glycogen back into glucose. Type.

Patient information leaflet
Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) describes a range of conditions caused by a build-up of fat within liver cells. Most people with NAFLD do not develop serious liver problems. The liver is in the u... Much of the food we eat is broken down by the body into a type of sugar called glucose. Glucose can't be stored so it is turned into a.

Patient information leaflet
IgA nephropathy
IgA nephropathy is a condition in which a protein causes damage to the kidneys. The protein is called immunoglobulin A or IgA. Nephropathy means an illness that damages the kidney. The main job of the kidneys is to clear waste materials from the body and maintain a normal balance of fluids and chemicals in the body. The kidneys also have other.

Patient information leaflet
Diabetic kidney disease
Diabetic kidney disease is a complication that occurs in some people with diabetes. Treatment aims to prevent or delay the progression of the disease. Also, it aims to reduce the risk of developing cardiovascular diseases such as heart attack and stroke which are much more common than average in people with this disease. What is diabetic kidney.

Patient information leaflet
Wilson's disease
Wilson's disease is a genetic disorder in which copper builds up in the body, mainly in the liver and brain. Without any treatment, the build-up of copper can cause serious symptoms. Treatment is with medication to remove the excess copper and/or to prevent a further build-up of copper. What is Wilson's disease. Wilson's disease is a condition.

Patient information leaflet
Diet in chronic kidney disease
Chronic kidney disease (CKD) is a common long-term condition where the kidneys aren't working as well as they should be. There are some dietary choices that are recommended for people with early CKD. People with more advanced CKD may be advised to follow a special diet, usually with the support of a specialist dietician. It's important for.
Further reading and references
- Glycogen storage disease type IX; MedlinePlus, National Library of Medicine.
- Beauchamp NJ, Dalton A, Ramaswami U, Niinikoski H, Mention K, Kenny P, Kolho KL, Raiman J, Walter J, Treacy E, Tanner S, Sharrard M. Glycogen storage disease type IX: High variability in clinical phenotype. Mol Genet Metab. 2007 Sep-Oct;92(1-2):88-99. doi: 10.1016/j.ymgme.2007.06.007. Epub 2007 Aug 3.
- Brushia RJ, Walsh DA. Phosphorylase kinase: the complexity of its regulation is reflected in the complexity of its structure. Front Biosci. 1999 Sep 15;4:D618-41. doi: 10.2741/brushia.
- Burwinkel B, Amat L, Gray RG, Matsuo N, Muroya K, Narisawa K, Sokol RJ, Vilaseca MA, Kilimann MW. Variability of biochemical and clinical phenotype in X-linked liver glycogenosis with mutations in the phosphorylase kinase PHKA2 gene. Hum Genet. 1998 Apr;102(4):423-9. doi: 10.1007/s004390050715.
- Burwinkel B, Maichele AJ, Aagenaes O, Bakker HD, Lerner A, Shin YS, Strachan JA, Kilimann MW. Autosomal glycogenosis of liver and muscle due to phosphorylase kinase deficiency is caused by mutations in the phosphorylase kinase beta subunit (PHKB). Hum Mol Genet. 1997 Jul;6(7):1109-15. doi: 10.1093/hmg/6.7.1109.
- Burwinkel B, Shiomi S, Al Zaben A, Kilimann MW. Liver glycogenosis due to phosphorylase kinase deficiency: PHKG2 gene structure and mutations associated with cirrhosis. Hum Mol Genet. 1998 Jan;7(1):149-54. doi: 10.1093/hmg/7.1.149.
- Herbert M, Goldstein JL, Rehder C, Austin S, Kishnani PS, Bali DS. Phosphorylase Kinase Deficiency. 2011 May 31 [updated 2018 Nov 1]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK55061/
- Wuyts W, Reyniers E, Ceuterick C, Storm K, de Barsy T, Martin JJ. Myopathy and phosphorylase kinase deficiency caused by a mutation in the PHKA1 gene. Am J Med Genet A. 2005 Feb 15;133A(1):82-4. doi: 10.1002/ajmg.a.30517.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

